Ignite Creation Date:
2024-05-05 @ 11:10 PM
Last Modification Date:
2024-10-26 @ 10:29 AM
Study NCT ID:
NCT01266083
Status:
COMPLETED
Last Update Posted:
2018-11-30
First Post:
2010-12-21
Brief Title:
WT-1 Analog Peptide Vaccine in Acute Myeloid Leukemia AML or Acute Lymphoblastic Leukemia ALL
Sponsor:
Sellas Life Sciences Group
Organization:
Sellas Life Sciences Group
Study Overview
Official Title:
Phase II Trial of a WT-1 Analog Peptide Vaccine in Patients in Complete Remission CR From Acute Myeloid Leukemia AML or Acute Lymphoblastic Leukemia ALL
Status:
COMPLETED
Status Verified Date:
2018-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine whether the WT1 vaccine causes an immune response which is safe and able to keep the leukemia from coming back
Detailed Description:
The purpose of this study is to determine whether the WT1 vaccine causes an immune response which is safe and able to keep the leukemia from coming back While vaccines have been used in infectious diseases like smallpox and measlesthe idea about using vaccines in a cancer like AMLALL is really a new use of the idea of vaccinesThe WT-1 vaccine is made up of protein pieces that the immune system can recognize as abnormal The doctor thinks that the WT-1 protein is important in AMLALL and using some lab tests they are still able to find some of it in the bone marrow By attacking this small amount of the protein they hope to get rid of any small amount of AML that is still in the body
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None